Neokem Labs Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 17-11-2024
- Paid Up Capital ₹ 0.10 M
as on 17-11-2024
- Company Age 3 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.40 M
as on 17-11-2024
- Revenue 475.44%
(FY 2023)
- Profit -673.95%
(FY 2023)
- Ebitda -230.80%
(FY 2023)
- Net Worth -907.11%
(FY 2023)
- Total Assets 282.94%
(FY 2023)
About Neokem Labs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.40 M.
Rakesh Sharma, Arun Kumar, Sanjay Bansal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24299DL2021PTC384262
- Company No.
384262
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jul 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Neokem Labs?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Sharma  | Director | 27-Jul-2021 | Current |
| Arun Kumar | Director | 27-Jul-2021 | Current |
| Sanjay Bansal | Director | 27-Jul-2021 | Current |
| Seema Sharma | Director | 27-Jul-2021 | Current |
Financial Performance of Neokem Labs.
Neokem Labs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 475.44% increase. The company also saw a substantial fall in profitability, with a 673.95% decrease in profit. The company's net worth observed a substantial decline by a decrease of 907.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neokem Labs?
Unlock access to Neokem Labs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Wisdom Pharma Private LimitedActive 1 year 5 months
Rakesh Sharma and Seema Sharma are mutual person
- Ideal Infrapromoters Private LimitedActive 17 years 7 months
Rakesh Sharma and Seema Sharma are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Mar 2023 | ₹2.40 M | Open |
How Many Employees Work at Neokem Labs?
Neokem Labs has a workforce of 29 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neokem Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neokem Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
